GAYLE KELLER: Open Payments
NPI 1508805391 · FALLS CITY, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$570 in 37 payments from 12 companies in 2025. Trend: 2023 $417 · 2024 $385 · 2025 $570
Food & beverage: $570
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $181 |
| Otsuka America Pharmaceutical, Inc. | 6 | $116 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $51 |
| Neurocrine BioSciences, Inc. | 3 | $50 |
| Novo Nordisk Inc | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Janssen Pharmaceuticals, Inc | 1 | $20 |
| Alkermes, Inc. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, INGREZZA, ABILIFY ASIMTUFII, REXULTI, Wegovy, UBRELVY, UZEDY.
Industry payments across NE — which companies pay providers there.
